Inclusion Criteria:  Participant must be ≥ 35 years of age, at the time of signing the informed consent. With or without DM (at least 50% of participants will have an HbA1c ≥ 6.5%* and/or a known diagnosis of DM) Male or female (at least 40% of participants must be male, and at least 40% must be female) Capable of giving signed informed consent as described in Appendix A  Exclusion Criteria:  As judged by the investigator, any evidence of a medical condition which in the investigator's opinion makes it undesirable for the participant to participate in the study for example, but not limited to, if a participant is critically unwell or requiring ongoing emergency treatment Any known eye condition that may preclude clear imaging of the retina for example; cataracts Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements. Previous enrolment in the present study with the exception of roll-in participants who may be re-screened and re-enrolled.